North America accounts for a major oncology biosimilars market share in 2023, followed by Europe. The growing cases of cancer, rising approvals of biosimilars for cancer treatment, and the advanced healthcare infrastructure are the factors anticipated to propel the oncology biosimilars market in North America. Biologics are the most expensive medicines in the US. Biosimilars […]